UK markets close in 3 hours 22 minutes

Aladdin Healthcare Technologies SE (ALDNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.30500.0000 (0.00%)
At close: 11:22AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3050
Open0.3050
BidN/A x N/A
AskN/A x N/A
Day's range0.3050 - 0.3050
52-week range0.2840 - 0.6700
Volume2,500
Avg. volume56
Market cap3.495M
Beta (5Y monthly)-0.14
PE ratio (TTM)N/A
EPS (TTM)-0.2970
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Aladdin Healthcare Technologies with new research findings on COVID-19 diagnosis

    DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Scientific publication14.07.2021 / 08:36 The issuer is solely responsible for the content of this announcement.Aladdin Healthcare Technologies with new research findings on COVID-19 diagnosis BERLIN/LONDON, July 14, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, is one of the co-authors of a high

  • EQS Group

    Aladdin Healthcare Technologies SE reports the sale of software and intellectual property

    Aladdin Healthcare Technologies SE / Key word(s): DisposalAladdin Healthcare Technologies SE reports the sale of software and intellectual property18-May-2021 / 12:46 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Aladdin Healthcare Technologies SE reports the sale of software and intellectual propertyBERLIN/LONDON, 18 May 2021 - Aladdin Healthcare Technologies SE (the "Company") reports that its 100% subsidiary Aladdin Healthcare Technologies Ltd ("Aladdin Ltd") has today completed the sale of specific software and intellectual property to a customer based in the People's Republic of China. As consideration for the sale, the customer has paid GBP 500,000 to Aladdin Ltd.Aladdin Ltd has developed and is developing various AI-driven technology products for the healthcare market. It has developed prototype AI-driven Drug Discovery Platform and Knowledge Graph which can be tailored to various areas of drug development. The software being sold is the above-described intellectual property but specifically to be used for small molecule drug discovery in the area of Alzheimer's and Dementia. Aladdin retains the rights to use it in other areas.Wade Menpes-SmithContact:Aladdin Healthcare Technologies SEUnter den Linden 1010117 BerlinTel 030 7700 140 449email: info@aladdinid.comwww.aladdinid.com18-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Aladdin Healthcare Technologies SE Unter den Linden 10 10117 Berlin Germany Phone: 030 700140449 E-mail: info@aladdinid.com Internet: www.aladdinid.com ISIN: DE000A12ULL2 WKN: A12ULL Listed: Regulated Market in Dusseldorf EQS News ID: 1197804 End of Announcement DGAP News Service